EHA 2023: New Results on Ibrutinib in Combination with Venetoclax in the First-line Treatment of CLL

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：447 / 447
页数：1
相关论文
共 50 条
  • [21] Ibrutinib/Venetoclax Produces Encouraging Results in Relapsed/ Refractory CLL
    Schuyler, Devon
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) : 93 - 93
  • [22] Characterization and Outcomes of the Spanish Patients Included in the GLOW and CAPTIVATE-FD Studies: Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
    Abrisqueta, Pau
    Lopez-Jimenez, Javier
    Osorio, Santiago
    Hernandez Rivas, Jose Angel
    de la Cruz, Fatima
    Magnano, Laura
    Maria Arguinano, Jose
    Gonzalez, Marcos
    de la Serna, Javier
    Szoke, Anita
    Neumayr, Lynne D.
    Diels, Joris
    Schioppa, Claudio A.
    Rubio Azpeitia, Eva
    Dominguez-Lubillo, Teresa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S359 - S359
  • [23] Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study
    Tam, Constantine S.
    Siddiqi, Tanya
    Allan, John N.
    Kipps, Thomas J.
    Flinn, Ian W.
    Kuss, Bryone J.
    Opat, Stephen
    Barr, Paul M.
    Tedeschi, Alessandra
    Jacobs, Ryan
    Badoux, Xavier C.
    Ghia, Paolo
    Sukbuntherng, Juthamas
    Salem, Ahmed Hamed
    Russell, Kristin
    Eckert, Karl
    Zhou, Cathy
    Ninomoto, Joi
    James, Danelle F.
    Wierda, William G.
    BLOOD, 2019, 134
  • [24] Updated CLL Guideline Broad Recommendation of Ibrutinib for all Patients in First-Line Therapy
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (7-8) : 419 - 419
  • [25] The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma
    Fowler, Nathan H.
    Nastoupil, Loretta
    De Vos, Sven
    Knapp, Mark
    Flinn, Ian W.
    Chen, Robert
    Advani, Ranjana H.
    Bhatia, Sumeet
    Martin, Peter
    Mena, Raul
    Davis, Richard Eric
    Neelapu, Sattva S.
    Eckert, Karl
    Ping, Jerry
    Co, Melannie
    Beaupre, Darrin M.
    Neuenburg, Jutta K.
    Palomba, M. Lia
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (04) : 650 - 660
  • [26] Phase 2 study of the combination of ibrutinib plus venetoclax in patients with treatment-naive CLL/SLL
    Wierda, William
    Siddiqi, Tanya
    Stevens, Don
    Flinn, Ian
    Ghia, Paolo
    Russell, Kristin
    Eckert, Karl
    Zhou, Cathy
    Ninomoto, Joi
    James, Danelle
    Tam, Constantine
    LEUKEMIA & LYMPHOMA, 2017, 58 : 89 - 90
  • [27] Does time to treatment matter with venetoclax as first-line treatment for AML?
    Baden, D.
    Wolgast, N.
    Pohlmann, A.
    Steinhaeuser, S.
    Baldus, C. D.
    Fransecky, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 139 - 139
  • [28] Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib
    Jacobs, Ryan
    Lu, Xiaoxiao
    Emond, Bruno
    Morrison, Laura
    Kinkead, Frederic
    Lefebvre, Patrick
    Lafeuille, Marie-Helene
    Khan, Wasiulla
    Wu, Linda
    Qureshi, Zaina P.
    Levy, Moshe Yair
    BLOOD, 2022, 140 : 1931 - 1933
  • [29] Initial Results of a Phase 2 Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL
    Rogers, Kerry A.
    McLaughlin, Eric
    Wei, Lai
    Bhat, Seema A.
    Crouse, Arianna
    Grever, Michael R.
    Jones, Dan
    Kittai, Adam S.
    Lozanski, Gerard
    Moran, Mollie
    Reid, Mark
    Sass, Ellen J.
    Suresh, Swetha
    Byrd, John C.
    Woyach, Jennifer A.
    BLOOD, 2023, 142
  • [30] Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials
    Tanriverdi, Lokman Hekim
    Sarici, Ahmet
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S349 - S349
12345